Spinal Cord Research Help
AboutCategoriesLatest ResearchContact
Subscribe
Spinal Cord Research Help

Making Spinal Cord Injury (SCI) Research Accessible to Everyone. Simplified summaries of the latest research, designed for patients, caregivers and anybody who's interested.

Quick Links

  • Home
  • About
  • Categories
  • Latest Research
  • Disclaimer

Contact

  • Contact Us
© 2025 Spinal Cord Research Help

All rights reserved.

  1. Home
  2. Research
  3. Spinal Cord Injury
  4. Chondroitinase activity can be transduced by a lentiviral vector in vitro and in vivo

Chondroitinase activity can be transduced by a lentiviral vector in vitro and in vivo

J Neurosci Methods, 2011 · DOI: 10.1016/j.jneumeth.2011.05.007 · Published: August 15, 2011

Spinal Cord InjuryNeurologyGenetics

Simple Explanation

The enzyme chondroitinase ABC (ChABC) can break down scar tissue after spinal cord injury, helping axons to regrow. Delivering ChABC continuously is difficult, so the researchers used a lentiviral vector (LV) to deliver the gene for ChABC. They created a lentiviral vector (Chase/LV) that encodes chondroitinase AC (Chase) and a green fluorescent protein (GFP) reporter. This allows them to track which cells are producing the enzyme. The study showed that cells infected with Chase/LV produced the enzyme, which broke down CSPGs and promoted axon growth in lab dishes and in the spinal cords of rats.

Study Duration
8 weeks
Participants
Adult female Sprague Dawley rats (225-250 g)
Evidence Level
Not specified

Key Findings

  • 1
    Neural precursor cells infected with Chase/LV expressed the GFP reporter, and the expression increased over time in culture, indicating successful transduction and expression of the transgene.
  • 2
    Supernatant from Chase/LV-infected cells degraded CSPG, as confirmed by dot blot assay and the ability of neurites to grow into the CSPG area in chick DRG cultures.
  • 3
    A single injection of Chase/LV into the spinal cord resulted in sustained secretion of the enzyme, with activity detected for 8 weeks by GFP expression and evidence of digested CSPG.

Research Summary

This study demonstrates the efficacy of a lentiviral vector (Chase/LV) encoding chondroitinase AC (Chase) in vitro and in vivo to degrade CSPGs. Chase/LV-infected cells showed sustained expression of the enzyme for up to 8 weeks after injection into the spinal cord, promoting axonal growth. The Chase/LV vector holds potential as a therapeutic tool to reduce scar inhibition and promote axonal growth and repair following central nervous system injury.

Practical Implications

Therapeutic Potential

Chase/LV vector can be used as a gene therapy tool to deliver chondroitinase to the site of injury in the CNS.

Scar Reduction

The use of Chase/LV can reduce scar inhibition by degrading CSPGs, promoting axonal growth and repair.

Sustained Delivery

Chase/LV allows for sustained and controlled delivery of the enzyme, overcoming the limitations of direct enzyme injection.

Study Limitations

  • 1
    The expression levels of GFP and Chase enzymatic activity were reduced at 8 weeks post-injection, indicating a decline in transgene expression over time.
  • 2
    The study only examined the effects of Chase/LV in the intact spinal cord and did not directly assess its efficacy in a spinal cord injury model.
  • 3
    Further studies are needed to evaluate the long-term effects of Chase/LV and its impact on functional recovery after spinal cord injury.

Your Feedback

Was this summary helpful?

Back to Spinal Cord Injury